Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: A double-blind, randomized Phase III clinical trial

International Journal of Hematology

Volumn 94, Issue 1, 2011, Pages 71-80

  Shirasugi, Yukari ^a   Ando, Kiyoshi ^a   Miyazaki, Koji ^b   Tomiyama, Yoshiaki ^c   Okamoto, Shinichiro ^d   Kurokawa, Mineo ^e   Kirito, Keita ^f   Yonemura, Yuji ^g   Mori, Shinichiro ^h   Usuki, Kensuke ⁱ   Iwato, Koji ^j   Hashino, Satoshi ^k   Wei, Helen ^l   Lizambri, Richard ^l  

^a TOKAI UNIVERSITY HOSPITAL   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c OSAKA UNIVERSITY HOSPITAL   (Japan)

^d KEIO UNIVERSITY HOSPITAL   (Japan)

^e UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^f YAMANASHI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^g KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^h KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

ⁱ Kanto Medical Center   (Japan)

^j ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^k HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^l AMGEN INC   (United States)

more..

Author keywords

Efficacy; Idiopathic thrombocytopenic purpura; Japan; Safety; TPO receptor agonist

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DANAZOL; IMMUNOGLOBULIN; PLACEBO; RITUXIMAB; ROMIPLOSTIM; VINBLASTINE; VINCRISTINE;

ADULT; BACKACHE; CHRONIC DISEASE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; JAPANESE; KIDNEY CALCIFICATION; LIMB PAIN; MALAISE; MALE; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SPLENECTOMY; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PLATELETS; DOUBLE-BLIND METHOD; DRUG TOXICITY; EDEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGITIS; PAIN; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 79960104101     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-011-0886-8     Document Type: Article

References (43)

1. Y Kurata 2007 Recent advances in the treatment of idiopathic thrombocytopenic purpura Rinsho Ketsueki 48 355 362
2. M Chang PA Nakagawa SA Williams 2003 Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro Blood 102 887 895 (Pubitemid 36917780)
3. T Ijichi M Muranishi K Shimura 2003 Idiopathic thrombocytopenic purpura and mononeuropathy multiplex Acta Haematol 110 33 35 (Pubitemid 37140402)
4. D Nugent R McMillan JL Nichol SJ Slichter 2009 Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production Br J Haematol 146 585 596
5. D Provan 2009 Characteristics of immune thrombocytopenic purpura: a guide for clinical practice Eur J Haematol Suppl. (71) 8 12
6. J Pruemer 2009 Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura Am J Health Syst Pharm 66 S4 S10
7. F Rodeghiero R Stasi T Gernsheimer 2009 Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group Blood 113 2386 2393
8. F Zhang X Chu L Wang 2006 Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura Eur J Haematol 76 427 431
9. S Deane SS Teuber ME Gershwin 2010 The geoepidemiology of immune thrombocytopenic purpura Autoimmun Rev 9 A342 A349
10. PF Fogarty 2009 Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation Hematol Oncol Clin North Am 23 1213 1221
11. D Provan R Stasi AC Newland 2010 International consensus report on the investigation and management of primary immune thrombocytopenia Blood 115 168 186
12. R Stasi E Stipa M Masi 1995 Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura Am J Med 98 436 442
13. DM Arnold A Bernotas I Nazi 2009 Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review Haematologica 94 850 856
14. Arnold DM, Stasi R. Does Helicobacter pylori eradication therapy result in a platelet count improvement in adults with immune thrombocytopenic purpura regardless of H. pylori infection? ASH evidence-based review 2008. Hematology Am Soc Hematol Educ Program. 2008;31-2.
15. K Fujimura M Kuwana Y Kurata 2005 Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan Int J Hematol 81 162 168 (Pubitemid 40270991)
16. M Kuwana Y Ikeda 2006 Helicobacter pylori and immune thrombocytopenic purpura: unsolved questions and controversies Int J Hematol 84 309 315 (Pubitemid 46606571)
17. T Suzuki M Matsushima A Masui 2005 Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial Am J Gastroenterol 100 1265 1270 (Pubitemid 40904347)
18. C Tsumoto K Tominaga H Okazaki 2009 Long-term efficacy of Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura: 7-year follow-up prospective study Ann Hematol 88 789 793
19. PE Abrahamson SA Hall M Feudjo-Tepie 2009 The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review Eur J Haematol 83 83 89
20. WM Schoonen G Kucera J Coalson 2009 Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database Br J Haematol 145 235 244
21. Y Kurata K Fujimura M Kuwana 2011 Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review Int J Hematol 93 329 335
22. R Stasi D Provan 2004 Management of immune thrombocytopenic purpura in adults Mayo Clin Proc 79 504 522 (Pubitemid 38401771)
23. Godeau B, Michel M. Treatment of chronic immune thrombocytopenic purpura in adults. Ann Hematol. 2010;89:55-60.
24. R McMillan 1997 Therapy for adults with refractory chronic immune thrombocytopenic purpura Ann Intern Med 126 307 314 (Pubitemid 27078779)
25. S Nomura K Dan T Hotta 2002 Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura Blood 100 728 730 (Pubitemid 34761148)
26. A Rank O Weigert H Ostermann 2010 Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle Biologics 4 139 145
27. Nplate (romiplostim), European Public Assessment Report. European Medicines Agency. 2009. Available at http://www.ema.europa.eu/ema/index.jsp? curl=pages/medicines/human/medicines/000942/human-med-000938.jsp&murl=menus/ medicines/medicines.jsp&jsenabled=true. Accessed 16 June 2011.
28. Romiplate prescribing information. 2011. http://www.mhlw.go.jp/stf/ shingi/2r985200000136yg-att/2r9852000001372i.pdf. Accessed 16 June 2011.
29. VJ Burroughs RW Maxey RA Levy 2002 Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment J Natl Med Assoc 94 1 26
30. HW Matthews 1995 Racial, ethnic and gender differences in response to medicines Drug Metabol Drug Interact 12 77 91
31. Y Kumagai T Fujita M Ozaki 2007 Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study J Clin Pharmacol 47 1489 1497 (Pubitemid 350115297)
32. Y Shirasugi K Ando S Hashino 2009 A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura Int J Hematol 90 157 165
33. JB Bussel DJ Kuter JN George 2006 AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP N Engl J Med 355 1672 1681 (Pubitemid 44583957)
34. DJ Kuter JB Bussel RM Lyons 2008 Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial Lancet 371 395 403 (Pubitemid 351181334)
35. Jawa V, Hokom M, Hu Z, et al. Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects. Ann Hematol 2010.
36. R Brookmeyer J Crowley 1982 A confidence interval for the median survival time Biometrics 38 39 41
37. JB Bussel DJ Kuter V Pullarkat 2009 Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP Blood 113 2161 2171
38. G Cheng MN Saleh C Marcher 2011 Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study Lancet. 377 393 402
39. DJ Kuter GJ Mufti BJ Bain 2009 Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim Blood 114 3748 3756
40. DJ Kuter M Rummel R Boccia 2010 Romiplostim or standard of care in patients with immune thrombocytopenia N Engl J Med 363 1889 1899
41. Saleh MN, Bussel JB, Meyer O, et al. Results of bone marrow examinations in patients with chronic immune thrombocytopenic purpura treated with eltrombopag [abstr]. Blood. 2009;114:1326.
42. E Gibiansky J Zhang D Williams 2011 Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura J Clin Pharmacol. 51 842 856
43. Promacta (eltrombopag) tablets. US prescribing information. GlaxoSmithKline: Research Triangle Park; 2010.